egfrviii-specific hinge-optimized cd3 ζ-stimulatory/41bb-co-stimulatory chimeric antigen receptor autologous t-lymphocytes
Cell therapyexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 15, 2020 (NCT05063682)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Epidermal growth factor receptor erbB1Immunity, passive
EGFR immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05063682 | Phase 1 | May 15, 2020 | Apollo Hospitals, Chennai, India, Chembrain LTD, Jyväskylä Central Hospital, University of Oulu |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Apollo Hospitals, Chennai, India | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Chembrain LTD | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Jyväskylä Central Hospital | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Oulu | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1